Vir Biotechnology Inc (MEX:VIR)

Q2 2026 Vir Biotechnology Inc Earnings Call Transcript

Aug 5, 2026 / 08:30 PM GMT

Release Date Price: MXN170

Transcript 10-Q8-K

Key Points

Positve

Vir Biotechnology Inc (VIR) reported compelling 96-week data from its Phase 2 SOLSTICE trial, showing 88% of patients achieved undetectable virus (TND) with the combination regimen, which a KOL called the best rate in 50 years of HDV treatment.
The company completed enrollment in all three registrational ECLIPSE trials, positioning it for a catalyst-rich period with top-line data expected from ECLIPSE 1 in Q4 2026 and ECLIPSE 2 and 3 in Q1 2027.
Vir Biotechnology Inc (VIR) strengthened its balance sheet significantly, ending Q2 2026 with approximately $1.01 billion in cash after receiving $315 million from Astellas, extending its cash runway into the second half of 2028.
The company is rapidly advancing its oncology pipeline, with VIR-5500 now enrolling patients in multiple expansion cohorts, including monotherapy and combination settings, with the ambition to initiate Phase 3 registrational trials as early as next year.
Vir Biotechnology Inc (VIR) completed Drug Substance Process Performance Qualification (PPQ) manufacturing for both elapsiran and tobevibart, a major milestone that de-risks the manufacturing process ahead of potential regulatory submissions.
The company believes its ECLIPSE 2 study, which includes patients switching from the approved therapy bulevirtide, provides a unique differentiation point as no competing program is expected to have comparable switch data at launch.

Negative

Vir Biotechnology Inc (VIR) faces significant management turnover, with the company actively searching for a new CMO and CFO, which could create uncertainty in execution.
The company's R&D expenses increased significantly year-over-year, driven by a $48 million milestone payment to Sanofi and higher manufacturing costs, which could pressure future margins.
The current U.S. HDV diagnosis rate remains low at approximately 10-15%, and despite efforts to improve testing, the company acknowledges it may only realistically plateau at around 25%, limiting the potential addressable market.
Vir Biotechnology Inc (VIR) faces competitive pressure from the recently approved bulevirtide, which has a high price point of around $283,000, and the company must demonstrate its differentiation to drive adoption.
The company's VIR-5818 program is still in early-stage signal-finding development, and the upcoming data update in the second half of 2026 is intended to inform dosing and identify which HER2-expressing populations warrant further study, indicating uncertainty about its path forward.
The company's financial performance is heavily reliant on collaboration revenue, as evidenced by the $238.9 million in license revenue recognized in Q2 2026, which may not be sustainable on a recurring basis.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

VIR.OQ - Vir Biotechnology, Inc.
Q2 2026 Vir Biotechnology Inc Earnings Call
Aug 05, 2026 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Hello and welcome to Veer Biotechnology's second quarter 2026 financial results and corporate update conference call. As a reminder, this call is being recorded. At this time, all participants are in a listen-only mode. After the speaker's prepared remarks, there will be a question-and-answer session. I will now turn the call over to Kiki Patel, Head of Investor Relations. You may begin, Kiki.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, operator, and welcome, everyone. Earlier today, we issued a press release reporting our second quarter 2026 financial results and

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.